FOLFIRI Chemotherapy Regimen
Regimen Definition and Components
FOLFIRI is a combination chemotherapy regimen consisting of leucovorin calcium (folinic acid), fluorouracil (5-FU), and irinotecan hydrochloride, administered as a biweekly infusional protocol for colorectal cancer treatment. 1
Standard Dosing Schedule
The established FOLFIRI protocol administered every 2 weeks includes: 2, 3
- Irinotecan 180 mg/m² IV infusion over 90 minutes on day 1 2, 4
- Leucovorin 400 mg/m² IV (or 200 mg/m² if using levo-leucovorin) as a 2-hour infusion on day 1 2, 5
- 5-FU 400 mg/m² IV bolus immediately following leucovorin on day 1 2, 3
- 5-FU 2,400 mg/m² continuous infusion over 46-48 hours (prescribe as 1,200 mg/m²/day × 2 days to minimize medication errors) 2, 5
Clinical Indications
FOLFIRI serves multiple roles in colorectal cancer management:
- First-line therapy for metastatic colorectal cancer, providing equivalent efficacy to FOLFOX with different toxicity profiles 2, 3
- Second-line therapy after failure of oxaliplatin-based regimens (FOLFOX/CAPOX) 2
- Conversion therapy for initially unresectable metastatic disease to achieve resectability 2, 3
Efficacy Profile
FOLFIRI demonstrates superior outcomes compared to fluoropyrimidine monotherapy: 2, 3
- Higher response rates (approximately 40-45%) 2, 6
- Longer progression-free survival (5-9 months) 2, 7, 6
- Improved overall survival when all three cytotoxics (fluoropyrimidine, oxaliplatin, irinotecan) are used sequentially 2, 3
- Median overall survival approaching 24-30 months when combined with targeted biologics 2
Toxicity Profile
FOLFIRI exhibits a distinct toxicity pattern compared to FOLFOX, with more alopecia and diarrhea but less polyneuropathy. 2, 3
Common grade 3-4 adverse events include: 8, 7, 9
- Neutropenia (36-52%) 8, 7
- Diarrhea (5-20%) 8, 7
- Leucopenia (15-18%) 8, 7
- Mucositis (less common but notable) 8
Critical safety consideration: Recent evidence suggests single-agent irinotecan may provide similar efficacy with reduced toxicity compared to full FOLFIRI in the second-line setting after oxaliplatin failure, though this remains controversial and FOLFIRI remains the guideline-recommended standard. 8
Comparison with Alternative Regimens
FOLFIRI and FOLFOX demonstrate equivalent activity as first-line therapy, making the choice dependent on toxicity considerations and planned treatment sequencing. 2, 3
- FOLFIRI preferred when avoiding cumulative neurotoxicity is priority 2
- FOLFOX preferred when diarrhea risk must be minimized 2
- Both serve as appropriate partners for biologic agents (bevacizumab, anti-EGFR antibodies) 2
The triplet regimen FOLFOXIRI (adding oxaliplatin to FOLFIRI) shows improved outcomes in selected patients but remains controversial due to increased toxicity. 2
Administration Considerations
Infusional 5-FU regimens are less toxic than bolus regimens and should be preferentially used. 2, 3
- Requires central venous access for continuous infusion 7
- Chemotherapy orders must specify 24-hour units (1,200 mg/m²/day, NOT 2,400 mg/m² over 48 hours) to prevent medication errors 5
- Never confuse leucovorin 400 mg/m² with levo-leucovorin 200 mg/m² dosing 5
- Modified regimens with lower leucovorin doses (20 mg/m²) show similar efficacy with acceptable tolerability 9
Treatment Duration and Monitoring
Treatment continues until disease progression, unacceptable toxicity, or achievement of treatment goals (resectability). 2, 3
- Consider treatment interruptions or de-escalation to fluoropyrimidine monotherapy if cumulative toxicity develops and disease control is achieved 3
- Sequential therapy starting with fluoropyrimidine alone remains valid for frail patients (approximately 15% of patients), though combination therapy is preferred when objective response is the goal 2, 3
- Monitor complete blood counts, liver function, and renal function before each cycle 5